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Multiple studies have assessed the real-world effectiveness of different Coronavirus 2019 (COVID-19) vaccination programs in the general population, in healthcare and 
other frontline workers and in care home residents1. Studies gen-
erally showed high effectiveness of the BNT162b2 mRNA vaccine 
(Pfizer-BioNTech) and the Oxford-AstraZeneca adenovirus vector 
vaccine, ChAdOx1 nCoV-19 (termed here ChAdOx1), against the 
Alpha (B.1.1.7) and preceding variants. More limited real-world 
effectiveness data are available for the mRNA-1273 (Moderna) vac-
cine2–4. Continued emergence of new SARS-CoV-2 variants poten-
tially threatens the success of vaccination programs, particularly 
as in vitro experiments suggest reduced neutralization activity of 
vaccine-elicited antibodies against emerging variants5,6. Of particu-
lar concern is the Delta variant (B.1.617.2), which has caused sharp 
rises in infections in many countries, including some with relatively 
high vaccination coverage, such as the United Kingdom (UK). In 
England, B.1.617.2 quickly became dominant after being classified 
as a variant of concern on 28 April 2021, reaching 61% of sequenced 
positives from the English symptomatic testing program in the 
week commencing on 17 May (https://assets.publishing.service. 
gov.uk/government/uploads/system/uploads/attachment_data/ 
file/991343/Variants_of_Concern_VOC_Technical_Briefing_14. 




Real-world data on vaccine effectiveness (VE) against B.1.617.2 
infections are currently limited. A test-negative case–control study 
using data to 16 May 2021 from the English symptomatic testing 
program suggested that the effectiveness after one BNT162b2 or 
ChAdOx1 vaccination was lower against symptomatic infection 
with B.1.617.2 (31%) than B.1.1.7 (49%)7. Reductions in effective-
ness against infection with B.1.617.2 versus B.1.1.7 were smaller after 
two doses of either vaccine. However, estimates from test-negative 
case–control studies might be biased if vaccination status influences 
test-seeking behavior of cases not requiring healthcare8. A recent 
study from Scotland also suggested reduced effectiveness against 
infection with B.1.617.2 versus B.1.1.7 after two doses of either vac-
cine9. However, the authors found no evidence that effectiveness on 
hospital admissions in individuals first testing positive varied with 
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The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) infections requires continuous re-evaluation, given the increasingly dominant B.1.617.2 (Delta) variant. In this 
study, we investigated the effectiveness of these vaccines in a large, community-based survey of randomly selected households 
across the United Kingdom. We found that the effectiveness of BNT162b2 and ChAdOx1 against infections (new polymerase 
chain reaction (PCR)-positive cases) with symptoms or high viral burden is reduced with the B.1.617.2 variant (absolute dif-
ference of 10–13% for BNT162b2 and 16% for ChAdOx1) compared to the B.1.1.7 (Alpha) variant. The effectiveness of two 
doses remains at least as great as protection afforded by prior natural infection. The dynamics of immunity after second doses 
differed significantly between BNT162b2 and ChAdOx1, with greater initial effectiveness against new PCR-positive cases 
but faster declines in protection against high viral burden and symptomatic infection with BNT162b2. There was no evidence 
that effectiveness varied by dosing interval, but protection was higher in vaccinated individuals after a prior infection and in 
younger adults. With B.1.617.2, infections occurring after two vaccinations had similar peak viral burden as those in unvacci-
nated individuals. SARS-CoV-2 vaccination still reduces new infections, but effectiveness and attenuation of peak viral burden 
are reduced with B.1.617.2.
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B.1.617.2 versus B.1.1.7, leaving it unclear to what extent the results 
for infection might be attributable to bias due to test-seeking behav-
ior being influenced by vaccination status8. A further contributor 
might be waning immunity, with two recent studies from Israel 
finding higher infection rates in those vaccinated earliest10,11.
We, therefore, assessed the effectiveness of the BNT162b2, 
ChAdOx1 and mRNA-1273 vaccines against new SARS-CoV-2 
PCR-positive cases using the Office for National Statistics (ONS) 
COVID-19 Infection Survey (CIS), a large, community-based 
survey of individuals living in randomly selected private house-
holds across the UK, where RT–PCR tests were performed after a 
pre-determined schedule, irrespective of symptoms, vaccination 
and prior infection12,13. Besides avoiding bias from test-seeking 
behavior changing after receipt of particular vaccines, other advan-
tages over existing studies7–10,14,15 include the ability to adjust for 
prior infection status and a wider range of potential confounders, 
including working in patient-facing healthcare, care homes or social 
care, household characteristics and (in)direct contact with hospitals 
or care homes.
We assessed VE based on overall RT–PCR positivity and split 
according to self-reported symptoms, cycle threshold (Ct) value 
(<30 versus ≥30) as a surrogate for viral load, from 1 December 
2020 (start of vaccination rollout) to 16 May 2021, when B.1.1.7 
dominated, and from 17 May 2021 to 1 August 2021, when B.1.1.7 
was replaced by B.1.617.2 (Extended Data Fig. 1), using calendar 
time as an instrumental variable for variant. In addition, in this 
B.1.617.2-dominant period, we investigated variation in vaccine 
effectiveness by time from second vaccination, long-term health 
conditions, age and prior infection. Given concerns that recent 
reduced effectiveness of BNT162b2 against (severe) infection in 
Israel could be due to the short interval between first and second 
vaccinations (vast majority, 3 weeks16), we also investigated the 
dosing interval for BNT162b2. In addition, we assessed viral burden 
in new PCR-positive cases occurring ≥14 d after second vaccination 
using Ct values.
Results
Visits and new PCR-positive cases included in analysis. During 
the B.1.1.7-dominant period, from 1 December 2020 to 16 May 
2021 (Extended Data Fig. 1), nose and throat RT–PCR results were 
obtained from 384,543 individuals aged 18 years or older (221,909 
households) at 2,580,021 visits (median (interquartile range (IQR)) 7 
(6–8)), of which 16,538 (0.6%) were the first PCR-positive cases in a 
new infection episode. During the B.1.617.2-dominant period, from 
17 May to 1 August 2021, results were obtained from 358,983 indi-
viduals (213,825 households) at 811,624 visits (median (IQR) 2 (2,3), 
3,123 (0.4%)) being the first PCR-positive cases. Characteristics at 
included visits are shown in Supplementary Table 1.
We classified each visit according to vaccination status and 
prior infection, as previously reported13 (Supplementary Table 2), 
considering individuals not yet vaccinated or >21 d before vacci-
nation without evidence of prior infection as the reference group. 
The vast majority of post-vaccination visits were with individuals 
who received BNT162b2 or ChAdOx1; there were only sufficient 
data to provide conclusive estimates after the first mRNA-1273 
dose (Extended Data Figs. 2 and 3 and Supplementary Table 3). The 
median (IQR) time since first vaccination for visits ≥21 d after the 
first vaccination but before the second was 47 (34–61), 43 (31–58) 
and 41 (31–52) for ChAdOx1, BNT162b2 and mRNA-1273, respec-
tively (taking 21 d as the time when protection from the first vaccina-
tion might be reasonably achieved17). The median (IQR) time from 
second vaccination for visits ≥14 d after the second vaccination was 
41 (27–57) d for ChAdOx1 and 59 (35–86) d for BNT162b2, respec-
tively (taking 14 d as the time when protection from the second 





















1 December 2020–16 
May 2021 (B.1.1.7)
59% (52–65%) 63% 
(55–69%)
77% (66–84%) 72% (50–84%) 78% (68–84%) 79% 
(56–90%)
60% (50–68%)
17 May 2021 
(B.1.617.2)
57% (50–63%) 46% 
(35–55%)
82% (75–87%) 71% (64–77%) 80% (77–83%) 67% (62–71%) 72% (58–82%)
Heterogeneity P 0.60 0.004 0.29 0.99 0.50 0.23 0.12
VE: Ct <30
1 December 2020–16 
May 2021 (B.1.1.7)
70% (65–74%) 74% 
(69–79%)
83% (75–89%) 79% (62–88%) 94% (91–96%) 86% (71–93%) 87% (84–90%)
17 May 2021 
(B.1.617.2)
62% (56–68%) 50% 
(41–59%)
81% (73–86%) 69% (61–76%) 84% (82–86%) 70% 
(65–73%)
77% (66–85%)
Heterogeneity P 0.04 <0.0001 0.57 0.25 <0.0001 0.04 0.02
VE: self-reported symptoms
1 December 2020–16 
May 2021 (B.1.1.7)
73% (68–76%) 73% 
(67–77%)
92% (88–95%) 84% (72–91%) 97% (96–98%) 97% 
(93–98%)
80% (75–84%)
17 May 2021 
(B.1.617.2)
58% (51–64%) 40% 
(28–50%)
93% (90–95%) 73% (66–79%) 84% (82–86%) 71% (66–74%) 82% (73–88%)
Heterogeneity P <0.0001 <0.0001 0.71 0.08 <0.0001 <0.0001 0.59
aRe-infection will be a variable amount of time previously, but it was not possible to split this owing to low numbers. Note: All estimates (VE = 100% × (1 odds ratio)) were obtained from a generalized 
linear model with a logit link comparing to the reference category of ‘Not vaccinated, not previously positive and ≥21 d before vaccination’ and using clustered robust standard errors. Heterogeneity P values 
were obtained using the two-sided Wald test without adjustment for multiple comparisons. Calendar time was split into two epochs when most cases detected in the survey were ORF1ab + N positive 
(B.1.1.7 compatible) and then when triple positives became dominant (B.1.617.2 compatible) (Extended Data Fig. 1). Estimates from the former are similar to those from individuals aged ≥16 years previously 
published on data to 8 May 2021 but with slightly wider 95% CIs due to splitting time after the second dose at 14 d in this analysis. See Supplementary Table 4 for unadjusted heterogeneity P values. VE 
post-second doses changes over time from vaccination (see Fig. 2 and Extended Data Figs. 4 and 5 for changes in individuals aged 18–64 years), so estimates in this table are an average over follow-up 
included in this analysis.
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vaccination might be reasonably achieved). The median (IQR) dos-
ing interval between first and second vaccination was 76 (68–78) d 
and 74 (62–77) d, respectively.
Effect of vaccination on new PCR-positive cases. Adjusting for 
multiple potential confounders (details in Supplementary Table 
1), in the B.1.1.7-dominant period the VE of both BNT162b2 and 
ChAdOx1 vaccines against new PCR-positive cases was similar in 
individuals ≥18 years of age to that previously reported to 8 May 
2021 in individuals ≥16 years of age13 (Table 1 and Supplementary 
Table 4).
In the B.1.617.2-dominant period, in individuals aged ≥18 
years, there was evidence of reduced effectiveness compared to the 
B.1.1.7-dominant period ≥21 d after the first ChAdOx1 vaccina-
tion but not ≥14 d after the second (heterogeneity P = 0.004 and 
P = 0.23, respectively). There was no evidence of reduced effec-
tiveness in the B.1.617.2-dominant period for BNT162b2 against 
all new PCR-positive cases (heterogeneity P = 0.60 and P = 0.23, 
respectively) (Table 1, Fig. 1 and Supplementary Table 4).
However, a decreasing number of visits remained in the unvac-
cinated reference group over time, particularly for individuals aged 
65 years or over (Extended Data Figs. 2 and 3). In particular, in the 
B.1.617.2-dominant period, less than 1% of visits of individuals aged 
65 years or over were in the unvaccinated reference group, making 
estimates of VE against this group challenging to interpret. Although 
reasonable numbers of individuals aged 18–64 years remained in 
the unvaccinated reference group in the B.1.617.2-dominant period, 
comparisons with the B.1.1.7-dominant period were not possible in 
this age group owing to low numbers of individuals having received 
two vaccinations before 17 May 2021; however, VE estimates in the 
B.1.617.2-dominant period were similar to all adults for both vac-
cines (Fig. 1, Tables 1 and 2 and Supplementary Table 4). To inves-
tigate VE in the B.1.617.2-dominant period further, we, therefore, 
focused on this younger age group.
In the B.1.617.2-dominant period, VE against new PCR-positive 
cases of individuals aged 18–64 years was significantly lower for 
ChAdOx1 versus BNT162b2 ≥21 d after one vaccination and ≥14 
d after two vaccinations (heterogeneity P = 0.001 and P < 0.0001, 
respectively; Table 2 and Supplementary Table 5). For both vac-
cines, having received two doses ≥14 d previously still provided 
significantly more protection than one dose ≥21 d previously 
(P < 0.0001). There was no evidence that the effectiveness of two 
ChAdOx1 vaccinations ≥14 d previously differed from the protec-
tion afforded by previous natural infection without vaccination 
Not vaccinated, previously positive
≥ 14 d after 2nd dose ChAdOx1
≥ 14 d after 2nd dose BNT162b2
≥ 21 d after 1st dose,
 no 2nd dose ChAdOx1
≥ 21 d after 1st dose,
 no 2nd dose BNT162b2
0 25 50 75 100




18−64, Delta: all infections, Ct <30, symptomatic
Not vaccinated, previously positive
≥ 14 d after 2nd dose ChAdOx1
≥ 14 d after 2nd dose BNT162b2
≥ 21 d after 1st dose,
 no 2nd dose ChAdOx1
≥ 21 d after 1st dose,
 no 2nd dose BNT162b2
0 25 50 75 100
Vaccine effectiveness (95% CI)
Alpha-dominant period
Delta-dominant period
18+, Alpha vs Delta: all infections
a
b
Fig. 1 | Protection against new PCR-positive cases. a, Protection against all new PCR-positive cases, case with Ct < 30, or cases with self-reported 
symptoms in individuals 18–64 years in the B.1.617.2-dominant period. b, Protection against all new PCR-positive cases in individuals older than 18 years in 
both the B.1.1.7- and B.1.617.2-dominant periods. All estimates (VE = 100% × (1 odds ratio)) were obtained from a generalized linear model with a logit link 
comparing to the reference category of ‘Not vaccinated, not previously positive and ≥21 d before vaccination’ and using clustered robust standard errors. 
The dots represent the point estimates (central estimate, 100% × (1 odds ratio)), and the error bars represent 95% CIs. Underlying counts are provided in 
Supplementary Table 2. VE estimates in Tables 1 and 2 for ≥18 years and 18–64 years, respectively.
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(heterogeneity P = 0.33), whereas two BNT162b2 vaccinations 
afforded greater protection (P = 0.04). Results were similar for indi-
viduals ≥18 years of age (Table 1). Effectiveness of a single dose of 
mRNA-1273 in individuals aged 18–64 years was at least as high as 
a single dose of BNT162b2 or ChAdOx1 (Supplementary Table 3 
and Table 2). Apparent greater effectiveness of a single mRNA-1273 
dose could potentially be driven by age, as individuals receiving 
mRNA-1273 were younger on average, and effectiveness appeared 
greater in younger individuals (Supplementary Table 6). There were 
insufficient data to estimate VE after a second mRNA-1273 dose 
(Extended Data Figs. 2 and 3).
Effect of time from second vaccination and subgroups. In the 
B.1.617.2-dominant period, in individuals 18–64 years of age, VE 
of BNT162b2 against new PCR-positive cases reduced over time 
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Fig. 2 | Protection against new PCR-positive cases since second dose. Note: Data were restricted to individuals aged 18–64 years and the B.1.617.2-dominant 
period. All estimates (VE = 100% × (1 odds ratio)) were obtained from a generalized linear model with a logit link comparing to the reference category of ‘Not 
vaccinated, not previously positive and ≥21 d before vaccination’ and using clustered robust standard errors. The error bars represent 95% CIs. See Extended 
Data Figs. 4 and 5 for effects on PCR-positive cases with Ct <30 or symptoms. See Table 3 for estimates of decline. See Supplementary Table 6 for estimates of 
VE within subgroups 14 d after second vaccination (intercept on panels below). lthc, self-reporting a long-term health condition.
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for ChAdOx1, but there was no formal evidence of heterogeneity 
(P = 0.14).
Approximately 10% of visits in the B.1.617.2-dominant 
period occurred in vaccinated individuals with evidence of prior 
SARS-CoV-2 infection (Supplementary Table 2). Protection against 
new PCR-positive cases was significantly higher for vaccinated indi-
viduals with prior infection than vaccinated individuals without 
prior infection for both ChAdOx1 and BNT162b2 (heterogeneity 
P < 0.0001 and P = 0.006, respectively; Supplementary Table 6).
VE was also higher in individuals aged 18–34 years than in indi-
viduals aged 35–64 years for both ChAdOx1 and BNT162b2 (het-
erogeneity P = 0.002 and P = 0.001, respectively). However, there 
was no evidence of differences between individuals reporting ver-
sus not reporting long-term health conditions or between <6 versus 
≥6 weeks (median (IQR) 25 (21–34) versus 72 (63–77) d) between 
the first and second BNT162b2 vaccination (heterogeneity P = 0.18; 
Supplementary Table 6).
Effect of vaccination by Ct and self-reported symptoms. 
Restricting new PCR-positive cases to those with Ct <30 (higher viral 
burden) or with symptoms, attenuations in VE in individuals aged 
≥18 years in the B.1.617.2-dominant versus the B.1.1.7-dominant 
period were more pronounced than against all new PCR-positive 
cases (Table 1 and Supplementary Table 4). Notably, attenuations 
in the B.1.617.2-dominant period now reached statistical signifi-
cance for BNT162b2 as well as ChAdOx1 (for example, hetero-
geneity P < 0.0001 ≥14 d post-second dose for both Ct <30 and 
symptomatic infections). In the B.1.617.2-dominant period, one 
or two BNT162b2 vaccinations still provided greater VE than 
ChAdOx1 against PCR-positive cases with Ct <30 or with symp-
toms in individuals aged ≥18 years (Table 1; P < 0.003) and 18–64 
years (Fig. 1, Table 2 and Supplementary Table 5; P < 0.001). In the 
B.1.617.2-dominant period, VE against PCR-positive cases with Ct 
≥30 (lower viral burden) or without self-reported symptoms was 
still lower than against PCR-positive cases with Ct <30 or with 
symptoms for all three vaccines (Table 2).
There was now formal evidence that the effectiveness of 
BNT162b2 against PCR-positive cases with Ct <30 or with symp-
toms declined faster ≥14 d after second vaccinations than for 
ChAdOx1 (heterogeneity P = 0.003 for both outcomes; Table 3, 
and Extended Data Figs. 4 and 5). Extrapolating declines beyond 
the observed follow-up, both vaccines would be equally effective 
against PCR-positive cases with Ct <30 139 d (4.6 months) after 
the second dose and 116 d (3.8 months) against PCR-positive cases 
with symptoms.
Viral burden and symptoms in PCR-positive individuals 
aged ≥18 years. In all 12,287 new PCR-positive cases in the 
B.1.1.7-dominant period, Ct values (inversely related to viral load) 
increased strongly with increasing time from first vaccination and 
number of doses (age/sex-adjusted trend P< 0.0001; Fig. 3a and 
Supplementary Table 7). Ct values were highest in individuals ≥14 
d after second vaccination—significantly higher than in individu-
als who were unvaccinated and not previously PCR/antibody posi-
tive but with no evidence that they differed from individuals who 
were unvaccinated but previously PCR/antibody positive (age/
sex-adjusted P = 0.02 and P = 0.72, respectively).
From 14 June 2021, after which more than 92% of PCR-positive 
cases with Ct <30 were B.1.617.2 compatible (Extended Data Fig. 
1), differences in Ct values between individuals who were unvac-
cinated and individuals ≥14 d after second vaccination had attenu-
ated substantially (age/sex-adjusted P = 0.35, heterogeneity versus 
B.1.1.7-dominant period P = 0.01), as had differences with individ-
uals who were unvaccinated but previously PCR/antibody positive. 
Mirroring the attenuation in Ct values, the difference between indi-
viduals who were unvaccinated and individuals ≥14 d after second 
vaccination in the percentages of PCR-positive cases reporting any 
or well-recognized COVID-19 symptoms (cough, fever or loss of 
taste/smell) significantly attenuated after 14 June 2021 (heteroge-
neity P < 0.0001 and P = 0.008 respectively; Extended Data Fig. 6). 
However, this was likely driven by lower Ct values, as the association 
between Ct and symptom reporting remained broadly similar after 
B.1.617.2 (Extended Data Fig. 7).
Considering all 1,736 PCR-positive cases ≥14 d after two 
ChAdOx2 or BNT162b2 vaccinations from 1 December 2020 
through 1 August 2021 (1,415 (82%), of whom had ≥1 prior nega-
tive swabs after their second vaccination), Ct values came from a 
mixture of two subpopulations (Fig. 3b). The low subpopulation 
had a mean Ct of 21.7 (95% confidence interval (CI), 21.2–22.2), 
and the high subpopulation had a mean Ct of 32.7 (95% CI, 32.5–
33.0), consistent with either mild or late identified infection. The 
relative percentage of new PCR-positive cases falling into these two 
subpopulations varied strongly over time (P < 0.0001; Fig. 3c), with 
the percentage in the low Ct (high viral burden) subpopulation 
Table 2 | Effectiveness in individuals aged 18–64 years in the B.1.617.2-dominant period




















58% (51–63%) 43% (31–52%) 83% (76–88%) 71% (63–77%) 82% (79–85%) 67% (62–71%) 73% (59–82%)
Ct <30 (Fig. 
1b)




59% (52–64%) 36% (23–47%) 93% (90–95%) 72% (65–78%) 86% (83–88%) 70% (66–74%) 83% (74–88%)




55% (48–61%) 50% (40–58%) 58% (41–70%) 66% (57–73%) 74% (69–78%) 57% (51–63%) 51% (26–67%)
aRe-infection will be a variable amount of time previously, but it was not possible to split this owing to low numbers. Note: All estimates (VE = 100% × (1 odds ratio)) as shown in Fig. 1 were obtained 
from a generalized linear model with a logit link comparing to the reference category of ‘Not vaccinated, not previously positive and ≥21 d before vaccination’ and using clustered robust standard errors. 
Heterogeneity P values were obtained using the two-sided Wald test without adjustment for multiple comparisons. See Supplementary Table 5 for unadjusted heterogeneity P values. See Table 1 for 
estimates in individuals ≥18 years of age in both B.1.1.7-dominant and B.1.617.2-dominant periods. VE post-second doses changes over time from vaccination (Fig. 2 and Extended Data Figs. 4 and 5), so 
estimates in this table are an average over follow-up included in this analysis.
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averaging 16%, 34% and 72% through 16 May 2021, 17 May–13 
June and 14 June onwards, respectively.
Independently of this effect of calendar time (reflecting B.1.1.7 
versus B.1.617.2 dominance), new PCR-positive cases were less 
likely to be in the low Ct subpopulation 14 d after two BNT162b2 
vaccinations than two ChAdOx1 vaccinations (adjusted odds ratio 
(aOR) = 0.33 (95% CI, 0.16–0.67), P = 0.002), but this likelihood 
increased significantly over time from second vaccination (aOR per 
month = 1.43 (95% CI, 1.07–1.91), P = 0.01; unadjusted in Fig. 3d; 
Supplementary Table 7 and Extended Data Fig. 8). In contrast, there 
was no evidence of changing likelihood over time for ChAdOx1 
(aOR per month = 0.97 (95% CI, 0.79–1.19), P = 0.78; heterogeneity 
P = 0.02). Overall, therefore, by around 3 months after second vac-
cination, the probability of being in the low-Ct subpopulation was 
similar for both BNT162b2 and ChAdOx1. Vaccine type and time 
from second vaccination had similar effects on the mean Ct within 
the low-Ct subpopulation, with higher Ct values in new PCR-positive 
cases 14 d after second BNT162b2 vaccination (P = 0.003), which 
then dropped significantly faster with time from second vaccina-
tion than for ChAdOx1 (interaction P = 0.01), leading to similar Ct 
values with both vaccines by around 3 months (Extended Data Fig. 
8b). Individuals who were previously PCR/antibody positive were 
less likely to belong to the low-Ct subpopulation compared to indi-
viduals without evidence of previous infection (P < 0.0001), while 
individuals who reported having long-term health conditions were 
also associated with a lower probability of belonging to the low-Ct 
subpopulation (P = 0.006), potentially reflecting protection in the 
former and longer duration of PCR positivity in the latter, leading 
to late infections being more likely to be identified through the fixed 
testing schedule. There were no additional effects of sex, age (unad-
justed in Extended Data Fig. 8b) or ethnicity on the probability of 
belonging to the low-Ct subpopulation (P > 0.15).
Anti-trimeric spike antibody (IgG) levels were measured in a 
subset of individuals, selected at random or based on longest study 
participation or prior swab positivity (Methods). A prior result was 
available for 846/1,736 (49%) new PCR-positive cases ≥14 d after 
two ChAdOx2 or BNT162b2 vaccinations, of which 795 (94%) were 
above the 42 ng ml−1 positivity threshold (Extended Data Fig. 9c) 
(median, 215 ng ml−1) (IQR 126–454). However, independently of 
factors in Supplementary Table 7, every doubling in IgG was asso-
ciated with 22% lower odds of a new PCR-positive case belonging 
to the low-Ct subpopulation (aOR = 0.78 (95% CI, 0.66–0.93), 
P = 0.007), with no evidence that this varied by vaccine type (hetero-
geneity P = 0.31). There was no evidence of association between IgG 
and mean Ct values within either subpopulation (P > 0.14). Most 
individuals with antibody measurements after a new PCR-positive 
test ≥14 d after second vaccination increased antibody levels after 
their new PCR-positive test, suggesting a boosting effect of new 
infections after vaccination (Extended Data Fig. 10).
Discussion
Our results suggest that vaccination with two doses of BNT162b2 
or ChAdOx1 still substantially reduces the risk of new PCR-positive 
SARS-CoV-2 infections. However, whereas the two vaccines pro-
vided similar benefits when B.1.1.7 was dominant, benefits from 
two ChAdOx1 doses are reduced more with B.1.617.2 than for two 
BNT162b2 doses, although two ChAdOx1 doses still provide simi-
lar protection as that from previous natural infection. Benefits from 
both vaccines are numerically greater against PCR-positive cases in 
patients with versus without self-reported symptoms and in patients 
with high- versus low-viral-burden PCR-positive cases, but the dif-
ference in effectiveness is smaller with B.1.617.2 for both vaccines.
The dynamics of protection varied over time from second vac-
cination and by vaccine type, with initially larger effectiveness 
with BNT162b2 than ChAdOx1, which then become more similar 
by ~4–5 months due to more rapid waning of effectiveness with 
BNT162b2, particularly against infections with Ct <30 or symp-
toms. Notably, there was no evidence that effectiveness depended 
on the interval between first and second BNT162b2 vaccinations 
(<6 weeks versus ≥6 weeks). Protection against new PCR-positive 
cases was significantly larger in vaccinated individuals with evi-
dence of prior infection than in vaccinated individuals without 
prior infection.
We also found greater effectiveness in individuals 18–34 years 
old than individuals 35–64 years old, although we were not able 
to jointly assess the degree to which this could have been caused 
by higher rates of previous infection in this group. We were 
unable to estimate VE in individuals 65 years of age and older in 
the B.1.617.2-dominant period, as very few individuals remained 
unvaccinated in the reference group; moreover, such individuals 
are unlikely to be representative. This challenge of diminishing and 
increasingly unrepresentative control groups also applies to other 
Table 3 | VE by time from second vaccination
Days since second dose Effectiveness against any new 
PCR-positive cases (95% CI)
Effectiveness against Ct <30 (high 
viral burden) infection (95% CI)
Effectiveness against symptomatic 
infection (95% CI)
BNT162b2 ChAdOx1 BNT162b2 ChAdOx1 BNT162b2 ChAdOx1
14 85% (79–90%) 68% (61–73%) 92% (87–95%) 69% (61–75%) 93% (89–96%) 72% (64–78%)
30 83% (78–88%) 66% (61–71%) 90% (86–93%) 67% (61–73%) 92% (87–95%) 70% (64–76%)
60 80% (76–83%) 64% (58–69%) 85% (81–89%) 65% (58–70%) 86% (82–90%) 67% (60–72%)
90 75% (70–80%) 61% (53–68%) 78% (72–82%) 61% (52–69%) 78% (72–82%) 63% (53–71%)
Relative reduction in 
effectiveness per month 
from second dose
22% declinea (6% 
decline to 41% 
decline)
7% decline (18% 
decline to 2% 
increase)
52% declinea (26% 
decline to 84% 
decline)
9% decline (22% 
decline to 3% 
increase)
63% declinea (30% 
decline to 103% 
decline)
11% decline (26% 
decline to 2% 
increase)
Test for evidence of 
change over time from 
second dose
P = 0.007 P = 0.15 P < 0.0001 P = 0.14 P < 0.0001 P = 0.10
Test for difference in 
relative rate of change 
between the two vaccines
P = 0.14 P = 0.003 P = 0.003
aWhen initial effectiveness is very high, modest relative declines per month have less effect on absolute effectiveness. Note: Data are restricted to individuals aged 18–64 years and the B.1.617.2-dominant 
period. All estimates (VE = 100% × (1 odds ratio)) were obtained from a generalized linear model with a logit link comparing to the reference category of ‘Not vaccinated, not previously positive and ≥21 d 
before vaccination’ and using clustered robust standard errors. P values were obtained using the two-sided Wald test without adjustment for multiple comparisons.
NATURE MEDICINE | www.nature.com/naturemedicine
ArticlesNATURE MEDICINE
designs, such as test-negative case–control, and will increasingly 
hinder assessment of VE at younger ages with increasing rollout 
(Extended Data Fig. 3).
Few studies have assessed VE during periods where the B.1.617.2 
variant dominated. A test-negative case–control study from the 
English symptomatic testing program suggested that the effective-
ness after one dose of either BNT162b2 or ChAdOx1 was lower 
against symptomatic infection with B.1.617.2 than B.1.1.7 (31% 
versus 49%, respectively), with smaller differences after two doses 
(BNT162b2, 88% versus 94%, respectively; ChAdOx1, 67% versus 
75%, respectively)7. There is little alternative to using observa-
tional data to assess VE against new variants, because additional 
placebo-controlled randomized trials would be unethical (although 
active comparator trials could still be performed). However, there 
are many biases in observational analyses18, particularly if symp-
tomatic testing is non-random and related to perceived efficacy8. 
Potential bias due to such health-seeking behavior is likely par-
ticularly pronounced for mild symptoms, included in many VE 
studies using routine symptomatic testing program data. This might 
be exacerbated by the generic nature of many symptoms prompt-
ing testing, which might be incidental, and misclassification due to 
individuals reporting symptoms when they want to get a test. As we 
demonstrated substantially lower VE against infections with high 
Ct or no reported symptoms, this would bias estimates toward lower 
effects, potentially differentially between vaccines.
Such bias is substantially reduced when testing schedules are fixed 
independent of symptom or vaccination status, as in our survey, 
or when using objective severe disease endpoints, such as hospital 
admissions and deaths. A recent study from Scotland9 found no sta-
tistical evidence of differential effectiveness against hospital admis-
sions with B.1.617.2 and B.1.1.7 (62% versus 72% in PCR-positive 
cases), although power was relatively limited. BNT162b2 effec-
tiveness against hospitalizations remained high when B.1.617.2 
dominated in Israel (88%, https://www.gov.il/BlobFolder/reports/
vaccine-efficacy-safety-follow-up-committee/he/files_publications_
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Fig. 3 | Ct values in new PCR-positive cases in individuals 18 years of age and older. a, All new PCR-positive cases by vaccination/reinfection status over 
time (n = 15,434). b, Distribution of Ct values in all PCR-positive cases ≥14 d after second dose (n = 1,736). c, Probability that each new PCR-positive case 
in b falls into the higher viral shedding class over time. d, Association between Ct values and time from second dose. Note: Boxes in a are median (IQR); 
b shows observed Ct values with the marginal density (black) and the densities estimated from a two-component mixture distribution. In a, the box plots 
show median values and upper and lower quartiles of the distribution, with whiskers extending from the hinge to the largest and smallest value no further 
than 1.5 times the IQR. In c, dotted lines show categorical effects of pre-specified calendar periods reflecting B.1.1.7 dominance and early and late B.1.617.2 
dominance (Extended Data Fig. 1); the solid line shows a continuous calendar time effect (linear on the log-odds scale). In d, months since second dose was 
truncated at the 95th percentile to avoid the undue influence of outliers. Spearman’s ρ = −0.09 (P = 0.004, two-sided t-test).
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against self-reported symptomatic SARS-CoV-2 infection (41% ver-
sus 97% previously)19.
Although testing behavior bias could contribute to these dif-
ferences, we also found a stronger protective effect against infec-
tions with higher viral burden and/or symptoms from BNT162b2 
and ChAdOx1 vaccines, although to a lesser degree than against 
B.1.1.7. One explanation could be differential effects of vaccina-
tion on mucosal and systemic immunity20. In theory, the former is 
more important for preventing carriage, transmission and infection 
becoming established, whereas the latter is more important for pre-
venting severe disease once infected21. Studies in rhesus macaques 
showed greater reductions in SARS-CoV-2 viral load in the lungs 
and prevention of pneumonia, without reducing viral loads in the 
upper respiratory tract with intramuscular ChAdOx1 (ref. 22), and 
protection against viral replication at much lower concentrations 
in the lower respiratory tract than in the upper respiratory tract 
with intramuscular mRNA-1273 (ref. 23). In mice, an experimen-
tal adenovirus vaccine induced strong systemic adaptive immune 
responses against SARS-CoV-2 and reduced infection in the lungs 
but minimal mucosal immune responses when administered intra-
muscularly24. Another explanation for differences in VE against 
infections with B.1.617.2 versus B.1.1.7 is that the former might have 
a replication advantage in airway human epithelial cells; increased 
infectivity at mucosal surfaces could facilitate antibody evasion25. A 
final explanation could be varying protection by time since second 
vaccination in the B.1.617.2-dominant period, which also differed 
between BNT162b2 and ChAdOx1. When such time-dependent 
effects are present, studies with different follow-up will inevitably 
get different ‘average’ results, and studies when B.1.1.7 dominated 
might predominantly reflect early effects. Regardless of explana-
tion, although protection against hospitalization and death is main-
tained, ‘booster’ vaccinations might not be needed, particularly 
because infection after vaccination might provide a natural anti-
body boost. However, declines in immunity against infection show 
that this needs to be monitored closely.
In addition to reduced VE, we found a substantial shift in viral 
burden in individuals who were infected despite two vaccinations 
with BNT162b2 or ChAdOx1 in the B.1.617.2-dominant period, 
with similar average Ct values to individuals infected without 
vaccination, and much more similar percentages reporting symp-
toms, driven by Ct. Although, with B.1.1.7, we13 and others26–28 
found that vaccinated individuals had lower viral burden (higher 
Ct values) than unvaccinated individuals, the greater number of 
new PCR-positive cases (1,736 ≥14d after second vaccination) 
allowed us to show that there are two different types of such infec-
tions: a low-viral-burden group that dominated early in 2021 and a 
high-viral-burden group that increased in frequency with B.1.617.2. 
Individuals receiving ChAdOx1 were more likely to fall into the lat-
ter group after their second vaccination, as were an increasing per-
centage of new PCR-positive individuals with increasing time from 
second BNT162b2 vaccination, mirroring changes in protection 
against new PCR positivity. Peak viral load, therefore, now appears 
similar in infected vaccinated and unvaccinated individuals, with 
potential implications for onward transmission risk, given the 
strong association between peak Ct and infectivity29. However, the 
degree to which this might translate into new infections is unclear; 
a greater percentage of virus might be non-viable in individuals who 
are vaccinated, and/or their viral loads might also decline faster, as 
suggested by a recent study of patients hospitalized with B.1.617.2 
(ref. 26) (supported by associations between higher Ct and higher 
antibody levels here and in ref. 30), leading to shorter periods ‘at risk’ 
for onwards transmission. Nevertheless, there might be implica-
tions for any policies that assume a low risk of onward transmission 
from vaccinated individuals (for example, relating to self-isolation 
and travel), despite vaccines both still protecting against infec-
tion, thereby still reducing transmission overall. This might be 
particularly important when vaccinated individuals are not aware 
of their infection status or perceive that their risk of transmission is 
low. Notably, individuals infected after second vaccination appeared 
to gain an antibody boost, and higher prior antibody levels were 
independently associated with lower viral burden.
The main study strength is its size and design including par-
ticipants from randomly selected private residential households 
in the community, tested following a fixed schedule, independent 
of symptoms and vaccination status, thereby avoiding bias due to 
test-seeking behavior that potentially affects many other stud-
ies assessing VE against SARS-CoV-2 infections8. Furthermore, 
we are able to adjust for risk factors that also affect vaccination 
but are typically not available in electronic health records, such as 
patient-facing healthcare work and long-term health conditions, 
and also adjusted for background ‘force of infection’ using flexible 
models for background infection rates varying by age, calendar time 
and geographical region. This should lead to less residual confound-
ing than studies relying on routine electronic healthcare data.
Our study has several limitations. Although we included a 
broad set of potential confounders, results might still be biased by 
unknown confounders or misclassification of prior infection sta-
tus—for example, due to having antibody measurements on only a 
subset. Participants are tested initially at weekly and then monthly 
visits, meaning that, when rates are increasing, as when B.1.617.2 
came to dominate, we expect to identify infected individuals earlier 
in their infection episode31,32, as shown and adjusted for in our Ct 
analysis. Late detection of older infections on the fixed visit sched-
ule means that some positives could be classified as having occurred 
shortly after vaccination, whereas the infection might actually have 
been acquired before vaccination, potentially diluting VE estimates. 
However, most infections ≥14 d after second vaccination had a 
preceding negative after second vaccination. To avoid misclassifi-
cation bias from erroneously classifying higher Ct positives where 
only ORF1ab + N genes were detected as B.1.1.7, our comparisons 
treated calendar periods as an instrumental variable, according to 
whether B.1.1.7 or B.1.617.2 was dominant, but this will likely lead 
to a small amount of bias in our VE estimates. In particular, it is 
expected to result in a small dilution bias when estimating the effect 
of the B.1.617.2 variant. We did not have information on severe out-
comes, against which VE might remain high as hospitalization and 
death rates have increased by only small amounts in the UK, despite 
large increases in the number of people testing positive (https://
coronavirus.data.gov.uk/).
In summary, with B.1.617.2, BNT162b2 and ChAdOx1 remain 
protective against any new PCR-positive cases and infections with 
higher viral burden or symptoms, but VE against these outcomes 
is reduced, with evidence of significantly different dynamics of 
immunity against infections with Ct <30 or symptoms after sec-
ond doses of the two vaccines. With B.1.617.2, those infections 
occurring despite either vaccine have similar peak viral burden to 
those in unvaccinated individuals. The effect on infectivity to oth-
ers is unknown but requires urgent investigation. It further argues 
for vaccinating as many of the population as possible, because 
unvaccinated individuals might not be protected by as substantial 
reductions in transmission among the immunized population as 
seen other infections, making herd immunity likely unachievable 
for emerging variants and requiring efforts to protect individuals 
themselves. Although the current preservation of VE against severe 
outcomes in other studies suggests that allowing ongoing virus 
transmission and nasopharyngeal viral presence might have lim-
ited consequences, the success of this strategy will ultimately rely on 
universal vaccination (currently not available to most worldwide); 
uniform protection induced by vaccines, including in older indi-
viduals; optimization of vaccine strategies to induce higher levels of 
mucosal and systemic immunity; and an absence of novel variants 
that might compromise VE against severe infection.
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Methods
The survey methods are the same as those described previously13 but are also 
described in detail below.
Study participants. The ONS CIS is a large household survey with longitudinal 
follow-up (ISRCTN21086382, https://www.ndm.ox.ac.uk/covid-19/covid-19- 
infection-survey/protocol-and-information-sheets) (details in refs. 12,13). The 
study received ethical approval from the South Central Berkshire B Research 
Ethics Committee (20/SC/0195). Private households are randomly selected 
on a continuous basis from address lists and previous surveys to provide a 
representative sample across the UK. After verbal agreement to participate, a 
study worker visited each selected household to take written informed consent for 
individuals aged 2 years and over. Parents or carers provided consent for those aged 
2–15 years; those aged 10–15 years also provided written assent. For the current 
analysis, we included only individuals aged 16 years and older who were potentially 
eligible for vaccination.
Individuals were asked about demographics, behaviors, work and vaccination 
uptake (https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey/case- 
record-forms). At the first visit, participants were asked for (optional) consent for 
follow-up visits every week for the next month and then monthly for 12 months 
from enrollment. At each visit, enrolled household members provided a nose and 
throat self-swab following instructions from the study worker. From a random 
10–20% of households, individuals age 16 years or older were invited to provide 
blood monthly for antibody testing from enrollment. From April 2021, additional 
participants were invited to provide blood samples monthly to assess vaccine 
responses, targeting 150,000 antibody tests per month, based on a combination 
of random selection and prioritization of individuals in the study for the longest 
period (independent of test results, vaccination or previous positive PCR tests). 
Throughout, individuals with a positive swab test and their household members 
were also invited to provide blood monthly for follow-up visits after this.
Laboratory testing. Swabs were couriered directly to the UK’s national Lighthouse 
laboratories (Glasgow and the National Biocentre in Milton Keynes (to 8 February 
2021)) where samples were tested within the national testing program using 
identical methodology. The presence of three SARS-CoV-2 genes (ORF1ab, 
nucleocapsid protein (N) and spike protein (S)) was identified using RT–PCR with 
the TaqPath RT–PCR COVID-19 kit (Thermo Fisher Scientific), analyzed using 
UgenTec FastFinder 3.300.5 (TagMan 2019-nCoV assay kit V2 UK NHS ABI 7500 
v2.1, UgenTec). The assay plugin contains an assay-specific algorithm and decision 
mechanism that allows conversion of the qualitative amplification assay raw data 
into test results with little manual intervention. Samples are called positive if either 
N or ORF1ab, or both, are detected. The S gene alone is not considered a reliable 
positive but could accompany other genes (that is, one, two or three gene positives).
Blood samples were couriered directly to the University of Oxford where they 
were tested for the SARS-CoV-2 antibody using an ELISA detecting anti-trimeric 
spike IgG33. Before 26 February 2021, the assay used fluorescence detection 
(positivity threshold, 8 million units)33. After this, it used a commercialized 
CE-marked version of the assay—the Thermo Fisher OmniPATH 384 Combi 
SARS-CoV-2 IgG ELISA (Thermo Fisher Scientific)—with the same antigen and a 
colorimetric detection system (positivity threshold, 42 ng ml−1 monoclonal antibody 
unit equivalents, determined from 3,840 samples run in parallel). From 27 February 
2021, samples were also tested using a Thermo Fisher Scientific N antibody.
Inclusion and exclusion criteria. This analysis included individuals aged 18 
years or older (that is, those who were eligible for vaccination) and all visits with 
positive or negative swab results from 1 December 2020 to 1 August 2021. The 
analysis of VE comparing B.1.1.7-dominant and B.1.617.2-dominant periods 
included all individuals aged ≥18 years; analyses of the B.1.617.2-dominant 
period were also restricted to visits in individuals aged 18–64 years, as the vast 
majority of individuals 65 years and older were vaccinated twice before B.1.617.2 
became dominant (Extended Data Figs. 2 and 3). Analyses of Ct values in new 
PCR-positive cases by vaccination status included all individuals aged ≥18 years.
Vaccination status. Individuals were asked about their vaccination status at visits, 
including type, number of doses and date(s). Individuals from England were also 
linked to administrative records from the National Immunisation Management 
Service (NIMS). We used records from NIMS where available; otherwise, we 
used records from the survey, because linkage was periodic, and NIMS does not 
contain information about vaccinations received abroad or in Northern Ireland, 
Scotland and Wales. Where records were available in both, agreement on type 
was 98%, and agreement on dates was 95% within ±7 d. A small number of visits 
after reported vaccination with either unknown or vaccines other than ChAdOx1, 
BNT162b2 or mRNA-1273 were excluded as these were too few to provide 
reliable estimates (for mRNA-1273, we included only the first dose and the period 
≥17 May because numbers were also too few before 17 May and for second doses 
(Extended Data Fig. 3)).
SARS-CoV-2-positive cases. PCR-positive results might be obtained at multiple 
visits after infection, so we grouped positive tests into episodes (cases). Whole 
genome sequencing is available on only a subset of positives, and only a subsample 
provides monthly blood samples for antibody status, so positive episodes were 
defined using study PCR results. We previously found that defining episodes based 
on 90 d, as suggested by the World Health Organisation (https://www.paho.org/ 
en/documents/interim-guidelines-detecting-cases-reinfection-sars-cov-2), led 
to higher than plausible risk of a new episode between 90 and 120 d, particularly 
for high-Ct infections13, suggesting that intermittent long-term PCR positivity 
could be contributing. Here, we, therefore, defined the start of a new ‘positive 
case’ as the date of (1) the first PCR-positive test in the study (not preceded by any 
study PCR-positive test by definition); (2) a PCR-positive test after four or more 
consecutive negative tests; or (3) a PCR-positive test at least 120 d after the start 
of a previous episode with one or more negative tests immediately preceding this. 
Positive cases were used to classify exposure groups and outcomes (see below).
Exposures. At each study visit, a participant was classified into one of 13 different 
exposure groups based on current vaccination status, study antibody and PCR tests 
and (for exposure classification only) positive swab tests linked from the English 
national testing program (https://www.gov.uk/government/publications/ 
nhs-test-and-trace-statistics-england-methodology/nhs-test-and-trace-statistics- 
england-methodology) (before visit), as follows:
 i. Visits from participants ≥21 d before first vaccination, including those 
currently with no vaccination date, with no prior PCR- or antibody-positive 
episode in the study, nor a positive swab test in the national testing program 
(as defined below) (‘Not vaccinated, not previously positive, ≥21 d before 
vaccination’) (baseline group);
 ii. Visits from participants 1–21 d before first vaccination with no prior PCR- or 
antibody-positive episode in the study, nor a positive swab test in the national 
testing program (‘Not vaccinated, not previously positive, 1–21 d before 
vaccination’)
 iii. Visits 0–20 d after a first vaccination with BNT162b2 (‘Vaccinated 0–20 d ago 
BNT162b2’);
 iv. Visits 0–20 d after a first vaccination with ChAdOx1 (‘Vaccinated 0–20 d ago 
ChAdOx1’);
 v. Visits 0–20 d after a first vaccination with mRNA-1273 (‘Vaccinated 0–20 d 
ago mRNA-1273’);
 vi. Visits 21 d or more after a first vaccination with BNT162b2 but before a sec-
ond vaccination (‘≥21 d after first dose, no second vaccination BNT162b2’);
 vii. Visits 21 d or more after a first vaccination with ChAdOx1 but before a sec-
ond vaccination (‘≥21 d after first dose, no second vaccination ChAdOx1’);
 viii. Visits 21 d or more after a first vaccination with mRNA-1273 but before a sec-
ond vaccination (‘≥21 d after first dose, no second vaccination mRNA-1273’);
 ix. Visits 0–13 d after a second vaccination with BNT162b2 (‘Second dose 0–13 d 
ago BNT162b2’);
 x. Visits 0–13 d after a second vaccination with ChAdOx1 (‘Second dose 0–13 d 
ago ChAdOx1’);
 xi. Visits ≥14 d after second vaccination with BNT162b2 (‘≥14 d after second 
dose BNT162b2’);
 xii. Visits ≥14 d after second vaccination with ChAdOx1 (‘≥14 d after second 
dose ChAdOx1’);
 xiii. Visits from participants who had not yet been vaccinated but were previously 
PCR/antibody positive in the study or had a positive swab test in the national 
testing program based on the definition of positive episodes above (‘Not vac-
cinated, previously positive’).
We chose these vaccination status categories empirically based on previous 
findings13. Exposure group ii (Not vaccinated, not previously positive, 1–21 d 
before vaccination) was included because there is inevitably a degree of transient 
reverse causality where vaccination appointments have to be rescheduled if 
someone tests positive in the weeks before the scheduled visit. Prior infection 
status was based on multiple sources, including previous PCR-positive episodes 
in the study, positive tests from the national testing program in England, positive 
S-antibody measurements before vaccination and N-antibody measurements. All 
participants were swabbed from enrollment and onwards, allowing assessment 
of prior infection status via this route. Everyone living in England (83% of the 
study population) was eligible to get tested via the national testing program 
if they experienced symptoms or this was required for workplace or school 
attendance. In total, 19% of participants had an S-antibody measurement before 
vaccination, and 32% of participants had at least two N-antibody measurements. 
We defined prior positivity as having either a previous PCR-positive episode 
or a positive S-antibody measurement more than 90 d before the visit or two 
consecutive positive N-antibody measurements more than 42 d before the visit. 
The choice of 90 d and 42 d was arbitrary but designed to exclude ongoing 
infections acquired previously being misattributed to current visits. Visits 
from vaccinated individuals (groups (iii)–(xii)) were defined irrespective of 
previous positivity (Supplementary Table 2) to reflect the effect of vaccination 
as being implemented in the UK (without regard to prior infection). However, 
in sensitivity analysis, we analyzed the effect of vaccination by prior infection 
status. Visits from the same participant were classified in different groups 
depending on their status at each visit.
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Outcomes. Analysis was based on visits, because these occur independently of 
symptoms and are, therefore, unbiased. Only the first test-positive visit in each 
new PCR-positive infection episode starting after 1 December 2020 was used, 
dropping all subsequent visits in the same infection episode and all negative 
visits before the first time that a participant could be considered ‘at risk’ for a 
subsequent new positive episode (as defined above), to avoid misattributing 
ongoing PCR positivity to visit characteristics and immortal time bias, respectively. 
Primary analysis included all new PCR-positive episodes. Secondary analyses 
considered infection severity, by classifying positives by Ct value (<30 or ≥30) and 
self-reported symptoms. The threshold Ct value of 30 is somewhat arbitrary but 
corresponds to ~150 copies per ml29 and is consistently used in the UK for many 
purposes, including algorithms for review of low-level positives at the laboratories 
where the PCR tests were performed and a threshold for attempting whole genome 
sequencing. For each positive test, a single Ct was calculated as the arithmetic 
mean across detected genes (Spearman correlation >0.98), and then the minimum 
value was taken across positives in the infection episode to reflect the greatest 
measured viral burden within an episode. To allow for pre-symptomatic positives 
being identified in the survey, any self-reported symptoms at any visit within 0–35 
d after the index positive in each infection episode were included (questions elicit 
symptoms in the last 7 d at each visit). Finally, positive infection episodes were 
classified as triple positive (ORF1ab + N + S or ORF1ab + S or N + S at least once 
across the episode; B.1.617.2 compatible), positive only for ORF1ab + N across the 
episode and never S-positive (B.1.1.7 compatible, because B.1.1.7 has deletions in 
the S gene leading to S gene target failure) or always positive only on a single gene. 
As S-gene target failure might also occur in high-Ct samples, the main analysis 
considered two periods of time when B.1.1.7 dominated (1 December 2020 to 16 
May 2021) and when B.1.617.2 dominated (17 May 2021 onwards) (Extended Data 
Fig. 1), further dividing analysis of Ct values at 14 June 2021.
Confounders. The following potential confounders were adjusted for in all  
models for VE as potential risk factors for acquiring SARS-CoV-2 infection 
(without variable selection): geographic area and age in years (see below),  
sex, ethnicity (white versus non-white as small numbers), index of multiple  





deprivation-measure-2017-nimdm2017), working in a care home, having a 
patient-facing role in health or social care, presence of long-term health conditions, 





pages/2/), direct or indirect contact with a hospital or care home, smoking status 
and visit frequency. Details are shown in Supplementary Table 1.
Statistical analysis. Associations among the different exposure groups and 
outcome (first positive test in an infection episode versus test negative) were 
evaluated with generalized linear models with a logit link. Robust standard errors 
were used to account for multiple visits per participant. To adjust for substantial 
confounding by calendar time and age, with non-linear effects of age, which 
are also different by region, we included both as restricted cubic splines and 
interactions between these splines and region/country (regions for England and 
country for Northern Ireland, Scotland and Wales). Furthermore, given previous 
observations of different positivity rates by age over time12, we added a tensor 
spline to model the interaction between age and calendar time with the restriction 
that the interaction is not doubly non-linear34. The primary analysis considered 
effect modification of each vaccine exposure group by time period (before 17 
May 2021 (B.1.1.7 dominant) or after 17 May 2021 (B.1.617.2 dominant)) in those 
aged ≥18 years. Secondary analyses considered variation over time from second 
vaccination (linear on the log-odds scale, truncating at the 95th percentile of 
observed days from second vaccination separately for each vaccine) and effect 
modification by long-term health conditions, dosing interval and prior infection 
status in the B.1.617.2-dominant period only in those aged 18–64 years. Pairwise 
comparisons of the exposure groups were performed unadjusted. Analysis was 
based on complete cases (>99% of observations).
For all infections, comparisons of Ct values by vaccine exposure groups used 
quantile (median) regression adjusted for age and sex. Associations between 
factors and Ct values in ‘breakthrough’ infections occurring ≥14 d after second 
vaccinations were assessed using mixture normal linear regression models with 
two component subpopulations (Bayesian Information Criterion 499.4 lower 
than single population). For these analyses of Ct values, we conducted backwards 
elimination (exit P = 0.05) for associations between factors and the latent class 
probabilities and separately with the Ct values in each subpopulation for the 
12 variables shown in Supplementary Table 7. We included interactions with 
vaccine in either part of the model type where these had interaction P < 0.05. 
We considered three knot-restricted natural cubic splines in continuous factors 
(calendar date of positive, age, interval between first and second vaccination and 
time since second vaccination) (knots at the 10th, 50th and 95th percentiles) if 
there was evidence of non-linearity at P < 0.01. To reduce the influence of outliers, 
we truncated the interval between first and second vaccination at 3 and 14 weeks 
and the time from second vaccination at the 95th percentile (118 d, 3.9 months).
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Data are still being collected for the COVID-19 Infection Survey. De-identified 
study data are available for access by accredited researchers in the ONS Secure 
Research Service (SRS) for accredited research purposes under part 5, chapter 5 
of the Digital Economy Act 2017. For further information about accreditation, 
contact research.support@ons.gov.uk or visit the SRS website.
Code availability
All statistical analyses of VE were performed using standard functions in the 
following R packages: ggplot2 (version 3.3.2), rms (version 6.0-1), dplyr (version 
1.0.2), emmeans (version 1.5.1), haven (version 2.3.1), sandwich (version 3.0-0), 
ggeffects (version 1.0.1), broom (version 0.7.2), multcomp (version 1.4–14) and Epi 
(version 2.44). Analyses of Ct values were performed using qreg and fmm in Stata 
version 16.1. Code used for data analysis is available upon reasonable request.
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Extended Data Fig. 1 | Characteristics of new PCR positive episodes over time. (a) gene positivity pattern overall, (b) gene positivity pattern restricted to 
episodes with cycle threshold (Ct) <30; (c) and mean Ct value and 95% CI in all positives. Note: analysis among those ≥18 years; ORF1ab + N + S (black) 
are compatible with wild-type and B.1.617.2 variants (S-gene positive); ORF1ab + N (gray) are compatible with the B.1.1.7 variant (S-gene negative). Those 
PCR-positives where only a single gene (N or ORF1ab were detected) cannot be classified (vast majority Ct>30). The percentage of PCR-positives with 
Ct<30 that were ORF1ab + N + S, compatible with B.1.617.2, increased from 6% the week commencing 10 May 2021, to 67% and 92% the weeks starting 
17 May and 14 June 2021, respectively. For panel (c), the number of new PCR positive tests in each calendar week are denoted at the top of the graph.
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Extended Data Fig. 2 | Visits included in analysis over time by vaccination status. The graphs (with different scales for the axes) show the number of 
visits by vaccination status, by calendar time and age category (dark: 18-34 year olds, intermediate: 35-64 year olds; light: 65+ year olds. The vertical line 
at 25 weeks indicates the start of the period dominated by B.1.617.2.
NATURE MEDICINE | www.nature.com/naturemedicine
ArticlesNATURE MEDICINE
Extended Data Fig. 3 | Proportion of visits by exposure. The vertical line at 25 weeks indicates the start of the period dominated by B.1.617.2.
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Extended Data Fig. 4 | Protection against PCR-positive episodes with Ct < 30. Note: data restricted to those aged 18-64 years old and the 
B.1.617.2-dominant period; lthc=self-reporting a long term health condition. All estimates (Vaccine effectiveness = 100% * (1-odds ratio)) were obtained 
from a generalised linear model with a logit link comparing to the reference category of ‘Not vaccinated, not previously positive and ≥21 days before 
vaccination’ and using clustered robust standard errors. The error bars represent 95% CIs. See Fig. 2 for effects on all PCR-positive episodes. See Table 3 
for estimates of overall decline over time. See Supplementary Table 6 for estimates of VE within subgroups 14 days after second vaccination (intercept on 
panels below).
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Extended Data Fig. 5 | Protection against PCR-positives with reported symptoms. Note: data restricted to those aged 18-64 years old and the 
B.1.617.2-dominant period; lthc=self-reporting a long term health condition. All estimates (Vaccine effectiveness = 100% * (1-odds ratio)) were obtained 
from a generalised linear model with a logit link comparing to the reference category of ‘Not vaccinated, not previously positive and ≥21 days before 
vaccination’ and using clustered robust standard errors. The error bars represent 95% CIs. See Fig. 2 for effects on all PCR-positive episodes. See Table 3 
for estimates of overall decline over time. See Supplementary Table 6 for estimates of VE within subgroups 14 days after second vaccination (intercept on 
panels below).
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Extended Data Fig. 6 | Symptoms reported in PCR-positives by subgroup. Note: data restricted to those 18+ years old. Error bars represent 95% 
confidence intervals. The number of tests in each group and the corresponding percentages with any symptoms and classic symptoms (cough, fever, 
anosmia, ageusia) are denoted in the top of the graph.
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Extended Data Fig. 7 | Probability of reporting symptoms in new PCR-positives. Note: data include all new PCR positives among those ≥18 years old. 
Panels (a) and (c) relate to any symptoms, while (b) and (d) relate to classic symptoms (cough, fever, loss of taste/smell). Panels (a) and (b) include all 
PCR-positives from 1 December 2020 to 1 August 2021; panels (c) and (d) fit separate models to the periods 1 December 2020-16 May 2021 (solid lines) 
and 14 June 2021-1 August 2021 (dashed lines).
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Extended Data Fig. 8 | Low Ct populations ≥14 days after second vaccination. (a) Adjusted effects of vaccine type and months since second vaccination 
on probability of belonging to the low Ct sub-population; (b) adjusted effects of vaccine type and months since second vaccination on Ct values within 
the low Ct sub-population; (c) adjusted effects of calendar time on Ct values within the low Ct sub-population. Shaded areas represent 95% confidence 
intervals. Note: data include all new PCR positives among those ≥18 years old; estimated at the reference category for other factors (27 April 2021, male, 
no previous PCR/antibody-positive, not reporting a long-term health condition). In (c), test for non-linearity in effect of calendar date p = 0.003 for low 
and <0.0001 for high Ct sub-population (two-sided Wald test without adjustment for multiple comparison).
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Extended Data Fig. 9 | Ct values in new PCR-positives ≥14 days after second vaccination. (a) by months since second vaccination (N = 1,736), (b) by age 
(N = 1,736) and (c) by most recent anti-trimeric spike IgG antibody measurement where available (N = 846). Note: in (a) red solid line shows 30 threshold 
used in main analysis. Short red lines show median within groups. In (c) antibody measurements taken median 30 (IQR 28-54) [range 25–91] days before 
the new PCR-positive, at or before the most recent prior negative swab and 14 days or more after first vaccination. 42 ng/ml is the positivity threshold. 
Overall association with Ct Spearman rho=0.08 (p = 0.002) for age (b), and 0.10 (p = 0.002) for IgG (c). P-values for the Spearman tests were obtained 
using a two-side t-test.
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Extended Data Fig. 10 | Antibody changes upon PCR-positive ≥14 days after second vaccination. (a) ChAdOx1 (N = 60), (b) BNT162b2 (N = 51]. Lines 
join repeated observations from the same individual. Median second vaccination date (IQR) 24 Apr 2021 (15 April-18 May) for ChAdOx1 and 5 April (9 
January-16 April 2021) for BNT162b2. Median (IQR) new PCR-positive date 13 June (30 May-19 June) for ChAdOx1 and 25 May 2021 (20 February-16 
June) for BNT162b2.
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